

# Polycystic Ovary Syndrome Market, 2021-2031 - Roots Analysis

Polycystic Ovary Syndrome Market, 2021-2031 - Roots Analysis

LONDON, ENGLAND, UNITED KINGDOM, October 26, 2021 /EINPresswire.com/ -- [Polycystic ovary syndrome](#) affects 1 in 10 women of childbearing age. The exact cause of the condition is unknown; however, obesity, high levels of inflammation and insulin resistance are the common risk factors

[Roots Analysis](#) is pleased to announce the publication of its recent study, titled, "[Polycystic Ovary Syndrome Market, 2021-2031.](#)"

The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapies over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:

- ▣ A detailed assessment of the therapeutic pipeline activity and therapeutic assessment of the products.
- ▣ Detailed profiles of the players that are engaged in the development of drug products / therapies for polycystic ovarian syndrome.
- ▣ An insightful market assessment summary, highlighting the clinical and commercial attractiveness of pipeline molecules (phase II and phase III).
- ▣ A detailed analysis identifying the key opinion leaders (KOLs), featuring a 2X2 analysis to assess the relative experience of certain KOLs.

### Example Highlights

A number of scientists from renowned universities are presently involved in clinical development efforts; these KOLs are mostly based in the US and China

**PCOS: Key Opinion Leaders (KOLs)**  
Regional Distribution

**Content Illustrative**  
(details available upon request)

---

### Example Highlights

Currently, there is no cure for the syndrome, however the affiliated symptoms can be treated using a combination of different types of medications

**List of PCOS Drugs**

S. No.	Drug Candidate	Company	YoE	HQ	POD	Drug Class	RoA	Symptoms	Combination Drugs	Line of Treatment
1	Adofo®		1781	USA	Marketed	Insulin-sensitizing agent	Oral	Insulin Resistance, Hirsutism, Infertility	Metformin	>1
6	Avanda®		1830	UK	Marketed	Insulin-sensitizing agent	Oral	Insulin Resistance, Hirsutism, Infertility, Menstrual Irregularities	Drospirenone / Ethinyl Estradiol	>1
9	Bayaz®		1863	Germany	Marketed	Contraceptives	Oral	Hyperandrogenism	NA	>1
13	Clomid/ Clomiphene®		1994	USA	Marketed	Contraceptives	Oral	Infertility	Letrozole	>1
16	Cur®		1876	France	Marketed	Insulin-sensitizing agent				
18	Enpresse®		1901	USA	Marketed	Contraceptives				
26	Ginette 35®		1991	USA	Marketed	Contraceptives				
34	Menopur®		1950	USA	Marketed	GnRH agonist				
41	Orythia®		1974	USA	Marketed	Contraceptives				
47	Vidzo®		1923	USA	Marketed	Insulin-sensitizing agent				
51	Xenical®		1896	USA	Marketed	Anti-Obesity				
56	Unnamed		2008	USA	Phase III	Anti-Androgens				
59	Otilissa®		2013	USA	Phase II	GnRH agonist				
62	Tiludronat		2016	USA	Phase II	CRF1 receptor antagonist				

*Information on 60+ drugs is available in the detailed report*  
Abbreviations: YoE: Year of Establishment, HQ: Headquarters, POD: Phase of Development, RoA: Route of Administration

**Content Illustrative**  
(details available upon request)

2021 © Roots Analysis

## Polycystic Ovarian Syndrome (PCOS)

## Polycystic Ovarian Syndrome (PCOS) - Roots Analysis

An insightful analysis of the patents filed / granted for polycystic ovary syndrome, since 2016, taking into consideration various parameters.  
 An in-depth analysis of grants awarded to various research institutes for the projects related to polycystic ovary syndrome, in the period between 2016 and April 2021.

A detailed analysis of completed, ongoing and planned clinical studies, based on the various relevant parameters.


A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

- Drug Class
- Insulin Sensitizing Agents
- Oral Contraceptives
- Anti-Androgens
- Anti-Obesity
- Route of Administration
- Oral
- Subcutaneous
- Intravenous
- Others
- Regional Distribution
- North America (US, Canada)
- Europe (France, Germany, Italy, Spain, UK)
- Asia-Pacific and Rest of the World (Australia, China, India and Japan)

Key companies covered in the report

- AbbVie
- Bayer
- GlaxoSmithKline
- Dupin Pharmaceuticals
- Merck
- Pfizer
- Takeda
- Teva Pharmaceuticals

For more information please click on the following link:



## Polycystic Ovarian Syndrome - Roots Analysis



<https://www.rootsanalysis.com/reports/polycystic-ovarian-syndrome-market.html>

#### Other Recent Offerings

1. Non-hormonal Therapies for Women's Health Market, 2021-2030
2. Squamous Non-Small Cell Lung Cancer: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031
3. Vascular Disrupting Agents Market, 2021-2030

#### About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you'd like help with your growing business needs, get in touch at [info@rootsanalysis.com](mailto:info@rootsanalysis.com)

#### Contact Information

Roots Analysis Private Limited  
Gaurav Chaudhary  
+1 (415) 800 3415  
[gaurav.chaudhary@rootsanalysis.com](mailto:gaurav.chaudhary@rootsanalysis.com)

Gaurav Chaudhary  
Roots Analysis  
+1 415-800-3415

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/554765953>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.